Interrupting rituximab treatment in relapsing-remitting multiple sclerosis; no evidence of rebound disease activity

ConclusionFindings are consistent with a low rate of RTX interruptions, with pregnancy and adverse events as most frequent reasons. A small proportion of patients switched due to breakthrough disease in context of incomplete B-lymphocyte depletion. Signs of ongoing disease activity in the remaining group was low regardless of whether a new DMT was started. These findings are consistent with a long acting effect of RTX in RRMS and absence of rebound disease activity phenomena upon stopping therapy.
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research